TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Severe congenital hemophilia A or B with an inhibitor.~* History of frequent spontaneous bleeding episodes.~* Male, age 18 or older.~* Affirmation of informed consent with signature confirmation before any trial-related activities.~Exclusion Criteria:~* Receiving prophylaxis treatment.~* Previous participation in a clinical trial evaluating a modified rFVIIa agent.~* Known positive antibody to FVII or FVIIa detected by central laboratory at screening.~* Have a coagulation disorder other than hemophilia A or B.~* Significant contraindication to participation.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1a (Type: EXPERIMENTAL): Coagulation Factor VIIa variant, 18 µg/kg by intravenous route
- Part 1b (Type: EXPERIMENTAL): Coagulation Factor VIIa variant, 30 µg/kg by subcutaneous route
- Part 2 (Type: EXPERIMENTAL): Coagulation Factor VIIa variant, 30, 60, 90, 120 µg/kg by subcutaneous route

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iliac Vein Stenting in Advanced Chronic Venous Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced Chronic Venous Insufficiency (CEAP 3-6) submitted to clinical treatment for at least 1 year with no response.~* Subject must be \> 18 and \< 80 years of age~* Willing to participate in and able to understand, read and sign the informed consent document before the planned procedure~* On duplex ultrasound: patent common femoral vein, and patent deep femoral vein, and/or femoral vein of the study leg~Exclusion Criteria:~* Subject cannot or will not provide written informed consent~* Previous venous stent implantation involving the study leg or inferior vena cava~* Previous venovenous bypass surgery involving the study leg~* Known metal allergy precluding endovascular stent implantation~* Known reaction or sensitivity to iodinated contrast that cannot be managed with premedication~* Subjects who are pregnant (women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment~* Acute deep venous thrombosis involving either leg~* Known history of chronic total occlusion of the common femoral vein of the study leg.~* Known history of thrombophilia (e.g., protein C or S deficiency, anti-thrombin III deficiency, presence of lupus anticoagulant, etc.)~* Venous compression caused by tumor encasement~* Venous outflow obstruction caused by tumor thrombus~* Life expectancy of less than 6 months~* Lower Extremity Arterial Insufficiency~* Elevated baseline blood creatinine (value greater than the upper limit of the normal range)~* Any concurrent disease or condition that, in the opinion of the Investigator, would make the subject unsuitable for participation in the study; examples include but are not limited to the inability to lie supine for the index procedure (e.g., severe congestive heart failure), thrombocytopenia or other hematological disorders associated with an unacceptable risk of bleeding, implanted orthopedic hardware that precludes proper imaging, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Clinical Treatment (Type: ACTIVE_COMPARATOR): Phlebotonics: Aminaftone 75 mg BID Limb elastic compression support (Elastic stockings: Venosan / Elastic Bandages: Atamed) Unna boot dressing
- Iliac vein stenting (Type: ACTIVE_COMPARATOR): Wallstent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Expanding HIV Testing Among Uganda Adults Who Utilize Traditional Healers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 year of age or older~* able to provide informed consent~* not known to be HIV infected~* willing to be contacted at 3 months following enrollment~* willing to complete an exit survey after 3 months~Exclusion Criteria:~* being under the age of 18 years~* incapable of giving informed consent~* previously being diagnosed with HIV~* being unwilling to receive HIV test results~* unwilling to participate in the testing intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healer HIV testing intervention (Type: EXPERIMENTAL): We will follow Ugandan National protocols to administer voluntary HIV testing at 9 TH practice locations throughout Mbarara District over a 9 month period.
- Healer control arm (Type: NO_INTERVENTION): Patients will undergo protcolized usual TH care at 8 practices, which include HIV education and a referral to receive VCT through existing resources. Study staff will contact the client at 3 months following enrollment to assess for self-report of VCT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extract of Ginkgo Biloba and Tardive Dyskinesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 to 60yrs~* Meeting Diagnostic and Statistical Manual of Mental Diseases, Fourth Edition(DSM-IV) criteria for schizophrenia or schizo-affective disorder~* Abnormal Involuntary Movement Scale (AIMS) score ≥2.~* Patients from whom informed, written consent is obtained.~* Patients who have been on a fixed dose of antipsychotic medication for at least 4 weeks prior to trial entry.~Exclusion Criteria:~* Significant neurological disorder other than TD~* Substance abuse~* Significant other medical illness~* Psychiatric disorder not stabilised~* Pregnancy or lactation~* Take antioxidants(such as Vitamin C)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Active treatment with EGb-761 capsules (80mg each capsule), 3 capsules each day for 12 weeks
- B (Type: PLACEBO_COMPARATOR): Matching placebo treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Have the ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use Protected Health Information in accordance with national and local patient privacy regulations.~* Have the ability to read and understand written English.~* Have access to the internet and are able to complete online assessments on a computer~* Have a relapsing form of Multiple Sclerosis and satisfy the approved therapeutic indication for dimethyl fumarate (DMF) per the United States Prescribing Information (USPI).~* Are being treated for relapsing forms of multiple sclerosis (MS) with glatiramer acetate (GA) but, per the Prescribing Physician, have a suboptimal response (e.g., suboptimal efficacy, intolerance, or poor adherence) to GA or have stopped treatment with GA for relapsing forms of MS as a result of suboptimal response within 30 days of enrollment.~* Have decided to initiate treatment with dimethyl fumarate (DMF) under routine clinical care. The decision to initiate treatment with DMF must precede enrollment.~* Have a complete blood count (CBC) available within 6 months of initiation of treatment with dimethyl fumarate (DMF).~Key Exclusion Criteria:~* Are unwilling or unable to comply with study requirements, or, are deemed unsuitable for study participation at the discretion of the Prescribing Physician.~* Have major comorbid conditions that would preclude their participation in the study as determined by the Prescribing Physician.~* Have a history of malignancy. (Patients with basal cell carcinoma that has been completely excised prior to study entry remain eligible.)~* Have a history of and/or current serious infections.~* Are pregnant or breastfeeding, or are planning to become pregnant or breastfeed.~* Are receiving concomitant disease modifying therapies other than glatiramer acetate (GA) or have initiated treatment with a new disease-modifying therapy since discontinuation of glatiramer acetate (GA).~* Are currently enrolled in any other clinical studies, with the exception of the dimethyl fumarate (DMF) Pregnancy Registry.~* Have received prior treatment with dimethyl fumarate (DMF).~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dimethyl fumarate (Type: None): To be taken according to the United States Prescribing Information (USPI)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Ages eligible for study: 12 years and above; genders eligible for study: both; prior steroid use: steroid-requiring~Inclusion Criteria:~* History of asthma for at least 12 months.~* Documented use of inhaled corticosteroid for at least 4 weeks prior to Screening Visit Demonstrate FEV-1 of 40-80% of predicted normal values at Screening and Baseline Visit.~* Documented reversibility of 15% within 12 months of Screening visit or at Screening Visit (15% increase from pre-FEV-1 levels following albuterol inhalation or nebulized albuterol administration).~* Symptoms of Asthma during Run-in.~* Females of childbearing potential must have a negative urine pregnancy test at Screening and Baseline Visits. Females are eligible only if they are not pregnant or lactating, and are either sterile or using acceptable methods of contraception~* Must otherwise be healthy.~* Provide written informed consent. Wishes of minors must be respected.~Exclusion Criteria:~* Life-threatening asthma within past year or during Run-In Period.~* History of systemic corticosteroid medication within 3 months before Screening Visit.~* History of omalizumab use within past 6 months.~* History of leukotriene receptor antagonist use, e.g. montelukast, within past week.~* Current evidence or history of any clinically significant disease or abnormality including uncontrolled hypertension, uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia.~* Upper or lower respiratory infection within 4 weeks prior to Screening visit or during Run-In Period~* Significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary disease \[COPD\], cystic fibrosis, bronchiectasis).~* Known Human Immunodeficiency Virus (HIV)-positive status.~* Smoking history equivalent to 10 pack years.~* Current smoking history within 12 months prior to Screening Visit.~* Current evidence or history of alcohol and/or substance abuse within 12 months prior to Screening visit.~* Patients who are confined in institution.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): FlutiForm 250/10
- 2 (Type: ACTIVE_COMPARATOR): FlutiForm 100/10
- 3 (Type: ACTIVE_COMPARATOR): Fluticasone 250
- 4 (Type: ACTIVE_COMPARATOR): Formoterol 10
- 5 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with paroxysmal or persistent atrial fibrillation; AND Undergoing first AF ablation; AND Age ≥ 18 years.~Exclusion Criteria:~* Previous left atrial ablation; Women currently pregnant; Mental or physical inability to take part in the study; Known terminally ill patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PVI, non-PV triggers (Type: ACTIVE_COMPARATOR): Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation.
- PVI, non-PV triggers & CS-LA connection (Type: ACTIVE_COMPARATOR): Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation in addition to coronary sinus-left atrium connection elimination. Distal coronary sinus pacing will be utilized to localize the earliest connection (aside from septal) from the coronary sinus to the left atrial musculature. Once localized, focal radiofrequency lesions will be applied at the discretion of the investigator until distal coronary sinus to left atrial connections are eliminated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female outpatients 18 years or older.~* Overactive bladder symptoms (subject-reported) for greater than or equal to 3 months.~* Currently sexually active with a male partner.~Exclusion Criteria:~* Diagnosed or suspected interstitial cystitis, uninvestigated hematuria, urogenital cancer, and interstitial or external radiation to the pelvis or external genitalia or clinically significant bladder outlet obstruction.~* Symptoms of incontinence being predominately stress urinary incontinence as determined by the investigator.~* Treated with antimuscarinic/ anticholinergic medication, for any reason including OAB, within the last 3 months or are expected to start therapy during the study treatment period.~* Any drug for urgency urinary incontinence (UUI) initiated within the past 3 months prior to Visit 1, with the exception of estrogen (topical or systemic) as long as treatment is not initiated within 4 weeks prior to Visit 1 (screening)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with total body weight of 10 kilograms(kg) or higher at Baseline. Beginning with protocol version 6.0, only subjects 3 years of age and older will be enrolled for the remainder of this study.~* Diagnosed with atopic dermatitis (AD) with onset of symptoms at least 6 months prior to baseline.~* Meets Hanifin and Rajka criteria for AD.~* Diagnosed with active severe AD defined by Eczema Area Severity Index (EASI), Validated Investigator's Global Assessment (IGA) and body surface area (BSA).~* Documented history (within 12 months prior to the Baseline Visit) of inadequate response or intolerance to topical corticosteroids (TCS) and topical calcineurin inhibitor (TCI) OR for whom use of TCS and TCIs is otherwise medically inadvisable.~Exclusion Criteria:~* Prior exposure to Janus Kinase (JAK) inhibitor.~* Requirement of prohibited medications during the study.~* Current use of known moderate or strong inhibitors or inducers of drug metabolizing enzymes within 30 days prior to the first dose of study drug and through the end of Part 1 of the study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Part 1; Cohort 1 (Type: EXPERIMENTAL): Participants, 6 to \<12 years of age, will receive low dose of upadacitinib.
- Part 1; Cohort 2 (Type: EXPERIMENTAL): Participants, 6 to \<12 years of age, will receive high dose of upadacitinib.
- Part 1; Cohort 3 (Type: EXPERIMENTAL): Participants, 2 to \<6 years of age, will receive low dose of upadacitinib.
- Part 1; Cohort 4 (Type: EXPERIMENTAL): Participants, 2 to \<6 years of age, will receive high dose of upadacitinib.
- Part 2 (Type: EXPERIMENTAL): Eligible participants who completed Part 1 will receive weight-dependant low dose of upadacitinib.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Idiopathic heart failure and/or arrhythmia of less than 3 months duration~* Endomyocardial biopsy diagnostic of idiopathic giant cell myocarditis~* Negative pregnancy test~Exclusion criteria:~* Clinical evidence of sepsis or active infection (e.g., meningitis or osteomyelitis)~* Pregnant~* Any contraindication to immunosuppression~* Allergy to cyclosporine or muromonab-CD3~* Creatinine greater than 2.5 mg/dL~* AST or ALT greater than 3 times upper limit of normal~* Other severe concurrent disease that would preclude study~* Unreliable or uncooperative subject

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-64 years old (both included) at screening.~* Diagnosis of atopic dermatitis (AD) (as defined by the American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year prior to screening.~* Subjects who have a recent history (within 6 months before screening) of inadequate response to treatment with topical medication, or for whom topical treatments are otherwise medically inadvisable.~* Eczema Area and Severity Index (EASI) score ≥12 at screening and ≥16 at baseline.~* Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) score ≥3 at screening and baseline.~* Body surface area (BSA) of AD involvement ≥10% at screening and baseline.~* Worst Daily Pruritus Numeric Rating Scale (NRS, weekly average) of ≥3 points at baseline.~Exclusion Criteria:~* Treatment with systemic immunosuppressive/immunomodulating medication, immunoglobulin/blood products, or phototherapy within 4 weeks or 5 half-lives prior to randomization, whichever is longer.~* Treatment with biologics within 5 half-lives (if known) or 16 weeks prior to randomization, whichever is longer.~* Treatment with topical corticosteroid(s) (TCS), topical calcineurin inhibitor(s) (TCI), topical phosphodiesterase-4 (PDE-4) inhibitor, or other topical prescription treatments within 1 week prior to randomization.~* Treatment with a live (attenuated) vaccine within 12 weeks prior to randomization.~* Clinically significant active chronic or acute infection requiring systemic treatment within 4 weeks prior to randomization that may compromise the safety of the subject.~* Skin infection within 1 week prior to the baseline visit.~* Presence of hepatitis B or C infection at screening.~* History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.~* Participant has a positive or indeterminate test for tuberculosis at screening.~* Participant is pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- LEO 138559 (Type: EXPERIMENTAL): Participants will receive injections of LEO 138559 from Week 0 (baseline) to Week 16 (end of treatment).
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive injections of placebo from Week 0 (baseline) to Week 16 (end of treatment).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete